Aggarwal C et al. Molecular testing in stage I-III non-small cell lung cancer: Approaches and challenges. Lung Cancer 2021;162:42-53. Abstract
Antonia SJ et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Eng J Med 2017;377(20):1919-29. Abstract
Aredo JV et al. Consolidation durvalumab should not be administered to patients with stage III EGFR-mutant NSCLC. J Thorac Oncol 2021;16(12):1994-8. Abstract
Aredo JV et al. Durvalumab for stage III EGFR-mutated NSCLC after definitive chemoradiotherapy. J Thorac Oncol 2021;16(6):1030-41. Abstract
Belluomini L et al. Anticipating EGFR targeting in early stages of lung cancer: Leave no stone unturned. Cells 2021;10(10):2685. Abstract
Burnett H et al. Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review. PLoS One 2021;16(3):e0247620. Abstract
Cooper AJ et al. Third-generation EGFR and ALK inhibitors: Mechanisms of resistance and management. Nat Rev Clin Oncol 2022;[Online ahead of print]. Abstract
Cortes J, Lang F. Third-line therapy for chronic myeloid leukemia: Current status and future directions. J Hematol Oncol 2021;14(1):44. Abstract
Felip E et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (Impower010): A randomised, multicentre, open-label, phase 3 trial. Lancet 2021;398(10308):1344-57. Abstract
Generalova O et al. Implementation of a cloud-based electronic patient-reported outcome (ePRO) platform in patients with advanced cancer. J Patient Rep Outcomes 2021;5(1):91. Abstract
Grant MJ et al. Efficacy of osimertinib in patients with EGFR mutant lung cancer harboring the uncommon exon 19 deletion, L747_A750>P. ASCO 2022;Abstract e21112.
Hellyer JA et al. Impact of tumor suppressor gene co-mutations on differential response to EGFR TKI therapy in EGFR L858R and exon 19 deletion lung cancer. Clin Lung Cancer 2022;23(3):264-72. Abstract
Hellyer JA et al. Role of consolidation durvalumab in patients with EGFR- and HER2-mutant unresectable stage III NSCLC. J Thorac Oncol 2021;16(5):868-72. Abstract
Hughes T et al. Trial in progress: A phase III study of asciminib vs an investigator-selected TKI in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP). EHA2022;Abstract PB1904.
Jänne PA et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer. Cancer Discov 2022;12(1):74-89. Abstract
Jänne PA et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). ASCO 2021;Abstract 9007.
Majem M et al. Health-related quality of life outcomes in patients with resected epidermal growth factor receptor-mutated non-small cell lung cancer who receive adjuvant osimertinib in the phase III ADAURA trail. Clin Cancer Res 2022;28(11):2286-96. Abstract
Melosky B et al. The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer. Ther Adv Med Oncol 2021;13:1758839211056306. Abstract
Neal JW et al. Randomized phase II study of 3 months or 2 years of adjuvant afatinib in patients with surgically resected stage I-III EGFR-mutant non-small-cell lung cancer. JCO Precis Oncol 2021;5:325-32. Abstract
No HJ et al. Characterization of metastatic non-small cell lung cancer and oligometastatic incidence in an era of changing treatment paradigms. Int J Radiat Oncol Biol Phys 2022;[Online ahead of print]. Abstract
Ou S-HI et al. Matching-adjusted indirect comparison (MAIC) of mobocertinib vs amivantamab in patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins). ASCO 2022;Abstract 9115.
Padda SK et al. A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer. Cancer Chemo Parma 2022;89(1):105-15. Abstract
Park K et al. Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: Initial results from the CRYSALIS phase I study. J Clin Oncol 2021;39(30):3391-402. Abstract
Piper-Vallillo AJ et al. High-dose osimertinib for CNS progression in EGFR+ NSCLC: A multi-institutional experience. JTO Clin Res Rep 2022;3(6):100328. Abstract
Ramalingam SS et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Eng J Med 2020;382(1):41-50. Abstract
Shah MP et al. EGFR exon 20 insertion NSCLC and response to platinum-based chemotherapy. Clin Lung Cancer 2022;23(2):e148-53. Abstract
Shah MP, Neal JW. Targeting acquired and intrinsic resistance mechanisms in epidermal growth factor receptor mutant non-small-cell lung cancer. Drugs 2022;82(6):649-62. Abstract
Shu CA et al. Amivantamab and lazertinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC) after progression on osimertinib in platinum-based chemotherapy: Updated results from CHRYSALIS-2. ASCO 2022;Abstract 9006.
Sotelo MJ et al. Recent advances and new insights in the management of early-stage epidermal growth factor receptor-mutated non-small-cell lung cancer. World J Clin Oncol 2021;12(10):912-25. Abstract
Spira AI et al. Mobocertinib in EGFR exon 20 insertion-positive metastatic NSCLC patients with disease control on prior EGFR TKI therapy. IASCL 2021;Abstract AO15.01.
Waliany S et al. Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic NSCLC. J Thorac Oncol 2021;16(12):2029-39. Abstract
White MN et al. Chemotherapy plus immunotherapy versus chemotherapy plus bevacizumab versus chemotherapy alone in EGFR-mutant NSCLC after progression on osimertinib. Clin Lung Cancer 2022;23(3):e210-21. Abstract
White MN et al. Combining osimertinib with chemotherapy in EGFR-mutant NSCLC at progression. Clin Lung Cancer 2021;22(3):201-9. Abstract
Wu Y-L et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Eng J Med 2020;383(18):1711-23. Abstract
Wu Y-L et al. Postoperative chemotherapy use and outcomes from ADAURA: Osimertinib as adjuvant therapy for resected EGFR-mutated NSCLC. J Thorac Oncol 2022;17(3):423-33. Abstract
Yu HA et al. ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib. ESMO 2021;Abstract 1239P.
Yu HA et al. Phase 1/2a study of CLN-081 in NSCLC patients with EGFR exon 20 insertion mutations (Ins20). ASCO 2022;Abstract 9007.
Zhou C et al. Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer: A phase 1/2 open-label nonrandomized clinical trial. JAMA Oncol 2021;7(12):[Online ahead of print]. Abstract